1. Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer

   • Sarah Sammons
   • Noah S. Kornblum
   • Kimberly L. Blackwell

   Review Article Open access 22 August 2018 Pages: 1 - 12

   

2. Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer

   • Sarah Sammons
   • Noah S. Kornblum
   • Kimberly L. Blackwell

   Correction 08 December 2018 Pages: 13 - 13

3. The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)

   • Albert Font
   • Raquel Luque
   • José Ángel Arranz

   Review Article 29 January 2019 Pages: 15 - 32

4. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx

   • Ilya Tsimafeyeu
   • Pavel Borisov
   • Gennady Bratslavsky

   Original Research Article 03 January 2019 Pages: 33 - 38

   

5. BI 853520, a FAK-Simile of Prior FAK Inhibitors?

   • Rachael Chang Lee
   • Hui K. Gan

   Commentary 07 March 2019 Pages: 39 - 41

6. Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

   • Maja J. A. de Jonge
   • Neeltje Steeghs
   • Lillian L. Siu

   Original Research Article Open access 11 February 2019 Pages: 43 - 55

   

7. Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors

   • Toshihiko Doi
   • James Chih-Hsin Yang
   • Chia-Chi Lin

   Original Research Article Open access 06 February 2019 Pages: 57 - 65

   

8. Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520

   • Remy B. Verheijen
   • Diane A. J. van der Biessen
   • Martijn P. Lolkema

   Original Research Article Open access 11 February 2019 Pages: 67 - 74

   

9. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

   • Maximilian J. Hochmair
   • Anna Buder
   • Martin Filipits

   Original Research Article Open access 12 December 2018 Pages: 75 - 83

   

10. Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry

    • Li Chia Chong
    • Amanda Rose Townsend
    • Timothy Jay Price

    Original Research Article 18 January 2019 Pages: 85 - 91

    

11. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy

    • Zhuanglin Li
    • Mingxue Wang
    • Changjiang Huang

    Original Research Article 11 January 2019 Pages: 93 - 105

    

12. Cabozantinib: A Review in Advanced Hepatocellular Carcinoma

    • Emma D. Deeks

    Adis Drug Evaluation 14 February 2019 Pages: 107 - 113